Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) stock closed at $36.08 on 3/1/24 after a major increase of 12.4%. Moreover, above average trading volume at 131% of normal accompanied the advance. The stock has risen 19.5% during the last week and has performed in line with the market over the last nine months.
Current PriceTarget Research Rating
With future capital returns forecasted to be in line with the cost of capital, ARWR is expected to continue to be Value Creation neutral.
Arrowhead Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects inconsistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Arrowhead Pharmaceuticals has a neutral Power Rating of 50 but a very low Appreciation Score of 3, leading to the Lowest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment